Vision & Mission
Our vision is to discover new, safe, and effective medications for treating neurological disorders.
Our mission is to develop novel proprietary small molecule to treat neuropathic pain.
Significance & Justification
- Neuropathic pain resulting from diabetes or cancer is a widespread and debilitating condition affecting 5% of people and astonishing 25% of diabetics worldwide.
- Current medications are not satisfactory due to poor efficacy or undesirable side effects.
- Clear & convincing evidence that both sigma (σ1) and serotonin (5-HT7) receptors directly participate in the pain pathway.
- Very profitable opportunity. Current market size is $2.4 Billion. Expected to grow to $7.5 Billion in 2020 in 7 major markets.
Innovation
- Daya’s innovative technology involves targeting both σ1 and 5-HT7 receptors with a single molecule to get an additive or synergistic effect.
- The dual σ1/ 5-HT7 receptor strategy for developing pain medication represents a unique and pioneering concept that has not been disclosed by others.
- Provisional patent application covering the composition of matter and use has been filed.
Current Results
- Proof of concept established. Daya has identified a new, proprietary, small molecule lead, DDD-028, which is orally active.
- DDD-028 binds selectively to σ1 and 5-HT7 receptors with Ki’s of 220 nM and 195 nM respectively.
- In off-target receptor profiling studies, DDD-028 shows no opioid activity.
- In vivo, DDD-028 is effective in reversing neuropathic pain in mouse model at very low dose of 1.00 mg/kg.
- DDD-028 is about 10-fold more potent than morphine and 180-fold more potent than gabapentin.
Future Plans (Preclinical Evaluation)
- Conduct pharmacokinetic, ADME, bioavailability, and toxicity studies.
- Evaluate DDD-028 in several neuropathic pain models: diabetic neuropathy, cancer pain, .
- Optimize manufacturing process under GLP/GMP protocol.
- File investigational new drug application (IND) with USFDA.